Background. Studies on the implementation of antibiotic stewardship programs (ASPs) in small hospitals are limited. Accreditation organizations now require all hospitals to have ASPs.
Core elements of effective ASPs and evidence-based guidelines for ASP implementation are available and highlight best practices in antibiotic stewardship [4, 7] . The majority of published studies on the effectiveness of ASPs are from large academic or community hospitals [2] [3] [4] . A significant portion of healthcare in the United States, however, takes place in small hospitals. In 2015, 73% of US hospitals had <200 beds (4057 hospitals) and accounted for 29% of all US inpatient bed days [8] . Limited studies on the effectiveness of antibiotic stewardship implementation have been performed in hospitals with <200 beds [9] [10] [11] [12] [13] [14] . Antibiotic use rates and selection patterns in these small hospitals are similar to those of large hospitals [15] [16] [17] , yet the majority of small hospitals lack formal ASP that meet Centers for Disease Control and Prevention (CDC) core elements [18] . The core elements that have proved effective may be difficult to implement in small hospitals owing to lack of resources and/or lack of infectious diseases (ID) expertise [18] [19] [20] . The objective of this real-world implementation study was to assess the effectiveness of 3 ASP strategies of escalating intensity designed specifically for small hospitals within a healthcare delivery system.
METHODS

Setting
Intermountain Healthcare (hereafter Intermountain) is a nonprofit healthcare delivery system that operates 22 hospitals in Utah and Idaho. All share an electronic medical record and an enterprise-wide data warehouse. This study focuses on the 15 small hospitals within this network. Three of the 15 small hospitals have designated pediatric units, 7 have intensive care units, and 5 are designated critical access hospitals. None had routine ID consultation available or an ASP before the study started. Intermountain's institutional review board provided a waiver of informed consent for this implementation study.
Study Design
We designed a cluster-randomized controlled intervention to evaluate 3 potentially effective antibiotic stewardship strategies. Each hospital was randomized to 1 of 3 ASP interventions (programs 1, 2, and 3; Figure 1 ). We compared antibiotic use within each program before and after the intervention. In keeping with other real-world implementation studies, secondary analyses were planned to include an interrupted time series (ITS) design to evaluate the impact of each strategy. Randomization of hospitals was stratified based on patient volume, and results were revealed to hospital leadership teams from July to December 2013. Hospital administration and clinical leadership were not blinded to which ASP program they were assigned. The intervention started March 2014.
Antibiotic Stewardship Interventions
We designed 3 ASPs with increasing levels of intensity and reliance on centralized support from ID pharmacists and physicians ( Figure 1 ). All hospitals were provided an educational curriculum and tools for implementation of basic antibiotic stewardship interventions (Supplementary Material). Clinicians at all participating hospitals had access to an ID telephone hotline, staffed by an attending ID physician 24 hours a day, 7 days a week to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter highlighting relevant national news and/ or updates from the study staff. Hospitals randomized to program 1 received only the above interventions.
Within program 2 and 3 hospitals, pharmacists received more intense antibiotic stewardship education, including online learning modules and a half-day in-person workshop, and implemented interventions including audit and feedback and preauthorization of select antibiotics [4] . Pharmacists in program 2 hospitals reviewed a limited list of antibiotics for audit and feedback, and those in program 3 hospitals reviewed an expanded list ( Figure 1 ).
For patients receiving a target antibiotic, on-site audit and feedback consisted of pharmacists' review of microbiology data to identify opportunities for antibiotic deescalation, intravenous to oral conversion, "bug-drug mismatches, " and/or indications for calling the ID hotline. The pharmacist would then contact Figure 1 . Components of the 3 antibiotic stewardship program interventions. For basic antibiotic stewardship, all hospitals required an indication to be given for every antibiotic order. To encourage a 48-hour antibiotic review, an email was sent daily to a designated email account when a patient had been taking an antibiotic for >48 hours. Educational materials were developed and disseminated for implementing antibiotic time-outs, intravenous to oral antibiotic conversion, antibiotic indications, evaluating for "bug-drug mismatches," and recommendations on when to call the infectious diseases (ID) hotline. A daily antibiotic stewardship checklist was created ,and posters were placed in each hospital highlighting the new antibiotic stewardship services. All materials were provided to all pharmacists and remained on-site in a resources binder. The ID hotline was staffed 24 hours a day, 7 days a week by a study ID attending physician and ID pharmacists. Advanced antibiotic stewardship education included didactic information and reference material on prospective audit and feedback, antibiotic deescalation procedures, the need for antibiotics targeting anaerobic bacteria (eg, double anaerobic activity), antibiotic allergy verification, and antibiotic restrictions. For the limited prospective audit and feedback (program 2), pharmacists reviewed all patients receiving vancomycin, piperacillin-tazobactam, imipenem, meropenem, and/or cefepime. For the expanded prospective audit and feedback (program 3), pharmacists reviewed all patients receiving vancomycin, piperacillin-tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and/or fluoroquinolones. For local antibiotic restriction (program 2), authorization of restricted antibiotics performed by local pharmacy staff; restricted antibiotics included daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, micafungin, caspofungin, voriconaozle, posaconazole, and amphotericin products. In program 3, authorization of restricted antibiotics was performed by an ID study pharmacist (restricted antibiotics as listed above), and an ID physician reviewed all positive blood cultures, cerebrospinal fluid cultures, positive stool tests for Clostridium difficile, and all positive cultures with multidrug-resistant organisms (Acinetobacter spp., carbapenem-resistant organisms, fluoroquinolone-resistant Escherichia coli, extended-spectrum β-lactamase producing organisms, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus).
the clinician with recommendations. Program 2 and 3 hospitals also implemented antibiotic restrictions. The following antibiotics were restricted: daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold-active antifungals. In program 2 hospitals, the local pharmacy staff preauthorized restricted antibiotics based on defined criteria. In program 3 hospitals, a study ID pharmacist reviewed all requests for restricted antibiotics, and an ID physician (E. S.) reviewed prespecified positive cultures (eg, all positive blood cultures, cultures with highly resistant Enterobacteraciae) Monday through Friday and contacted providers with recommendations.
Antibiotic Consumption Data
Antibiotic use data for all Intermountain hospitals has been submitted to the CDC's National Healthcare Safety Network's Antimicrobial Use module since January 2011 [15, 21, 22] . The data include monthly antibiotic use for each facility stratified by patient-care location, expressed as days of therapy per 1000 days present. Patient-level data are not submitted. Emergency department and pre-and postoperative units are not included in the National Healthcare Safety Network data. Hospital days and antibiotic use from miscellaneous units (eg, maternity and psychiatry) were excluded from all analyses owing to the variable size and presence of these units and historically low antibiotic use [15] . Only enteral or parenteral antibiotics were included; antifungal, antimycobacterial, and antiviral drugs were excluded. Broad-spectrum antibiotics were defined as aminoglycosides, fluoroquinolones, aztreonam, ceftazidime, cefepime, ceftaroline, carbapenems, piperacillin-tazobactam, colistin, vancomycin, daptomycin, and linezolid.
Statistical Analysis
Primary Analysis
Our prespecified primary analysis evaluated change in total antibiotic use between the baseline (January through December 2013) and intervention (April 2014 through June 2015) periods while accounting for the cluster-randomized design [23] . The analysis estimated the effect of each program type versus baseline care using prepost comparisons to provide ratios of the rates of total antibiotic use between the intervention and baseline periods within each program type. Our primary randomized comparisons of the effectiveness of the programs with each other were based on pairwise comparisons of these prepost changes between the 3 programs (program 3 vs 1, 2 vs 1, and 3 vs 2).
The analysis used a generalized linear mixed-effects (GLMM) negative binomial model [24] with an offset for days present to relate the 3 programs to the outcome, measured as monthly days of therapy within floor types for each hospital. Random effects for facility and the interaction between facility and floor type accounted for clustering. The model included terms to account for seasonal variation and differences in mean rates of antibiotic use between floor types and, in accordance with the randomized design, assumed equal baseline means for the 3 programs to increase power [25] . We hypothesized that the program 1 hospitals would not change the rate of antibiotic prescribing from baseline but that program 2 and 3 hospitals would reduce antibiotic use by 10% and 20%, respectively.
Secondary Analyses
Similar GLMMs evaluated the effects of the program types on broad-spectrum antibiotic use, which was our main secondary outcome, as well as restricted antibiotic use, 30-day readmission rate, 30-day mortality rate, hospital length of stay, and C. difficile incidence. These analyses included modifications to account for the distribution and level of aggregation of each outcome. For both the primary and secondary outcomes, we used corresponding fixed-effect models to estimate the effect of each program versus baseline care based on separate prepost comparisons within each hospital. These models included terms for the treatment period, hospital, the interaction of treatment period with hospital, floor type, and seasonal variation.
To account for trends over longer periods of time, we repeated our analyses of total and broad-spectrum antibiotic use using an ITS design to estimate the impact of the program types on the trend of antibiotic use over time [26] . This was made possible by the CDC's allowing the study team to back-populate the database for an additional 2 years to improve estimation of baseline trends. Summary rate ratio (RR) point estimates were calculated for each program by comparing the antibiotic use rate during the midpoint of the intervention period to the projected rate based on the trend from the extended baseline period (Supplementary Figure 1) . We again used GLMMs for negative binomial outcomes, with random intercepts, baseline slopes, and treatment effects to account for hospital clustering, and an additional random effect for the hospital by floor-type interaction. To obtain appropriate convergence, the model assumed that serial correlations were accounted for by the indicated fixed-and random-effects terms, without additional terms to account for potential auto-regressive errors. Corresponding fixed-effect analyses provided center-specific estimates of the program effects. (See the Supplementary Statistical Methods for additional details regarding the analyses.)
Multiple Comparisons
For both the primary and main secondary outcomes, we conservatively used the Tukey-Kramer adjustment to test each pairwise comparison among the 3 program types with an overall type I error of .05 [27] . Other secondary comparisons, including within-group comparisons of the primary and main secondary outcomes versus standard of care, were performed without multiple-comparison adjustment.
RESULTS
The 15 participating hospitals ranged in size from 14 
Prepost Comparison of Antibiotic Use
Total and broad-spectrum antibiotic use by month used in the prepost comparison for each program is shown in the upper panel of Figure 2 .
Antibiotic Changes Within Programs
Total antibiotic use declined 11% from baseline during the intervention period (RR, Table 1 and Figure 3 ). Significant variability of the impact of the intervention was observed among the hospitals in each program type (Figure 3) . A similar pattern was observed for use of broad-spectrum antibiotics. Use of broad-spectrum antibiotics was reduced by 24% (RR, 0.76; CI, .63-.91) in program 3 hospitals. No statistically significant reductions in broad-spectrum antibiotics were observed in program 1 or 2 hospitals (Table 1 and Figure 3 ). Restricted antibiotic use was analyzed after aggregating days of therapy across floor types within each hospital due to low rates of use. Use of restricted antibiotics declined by 86% (RR, 0.14; CI, .06-. 
Antibiotic Changes Between Programs
In our primary analysis comparing the magnitude of change between programs based on the randomized design, program 3 hospitals had greater observed reductions in total, broad-spectrum, and restricted antibiotic use than program 1 or 2 hospitals, but none of these differences met the prespecified threshold for statistical significance after accounting for multiple comparisons (Table 1 and Supplementary Table 5 ).
ITS Comparison of Antibiotic Use
Monthly total and broad-spectrum antibiotics used during the extended baseline, implementation, and intervention periods for the ITS analyses are shown in Figure 2 (lower panel) . The summary RR point estimates for within-and between-program differences were similar to those in the prepost analysis for both total and broad-spectrum antibiotic use (Table 1 and Figure 4) . (See the Supplementary Tables 6 and 7 for additional details.)
Clinical Outcomes
No statistically significant differences in mortality, 30-day readmission, and hospital length of stay were observed in any of the programs between the 1-year baseline and intervention periods (Supplementary Table 8 ). The incidence of C. difficile in the study hospitals during the baseline and intervention periods was low, and model convergence was not obtained. The C. difficile rates for program 1 were 0.47 cases per 1000 days present during the baseline period and 0.73 during the intervention period. The rates of C. difficile in the baseline and intervention period were 0.93 and 0.82 for program 2 and 0.41 and 0.36 for program 3, respectively (Supplementary Table 8 ).
ID Telephone Hotline
The ID hotline recorded 1006 calls for case discussions during the 15-month intervention (median, 62 case discussions per month; range, 48-83). Of these, 83% were received Monday through Friday. The call duration was 5 to 15 minutes for 48% of calls, and ≤5 minutes for 47%. The rate of hotline use varied by program, with 1.6, 13, and 10 calls per 1000 days present for programs 1, 2, and 3, respectively.
DISCUSSION
This multicenter, cluster-randomized intervention compared the effect of 3 ASPs of escalating intensity on antibiotic use in small hospitals. Only hospitals that implemented the most intensive ASP intervention (program 3), which used a combination of on-site pharmacist review and central ID support services to implement a comprehensive ASP experienced a reduction in total (11%) and broad-spectrum (24%) antibiotic use compared with baseline. When the effects of the 3 program types were compared, the magnitude of change was greater for program 3 hospitals, but none of the differences between programs were statistically significant.
The magnitude of reduction in antibiotic use observed in program 3 hospitals is consistent with findings in studies conducted in large academic or community hospitals [2] . Our study has several important strengths relative to previous antibiotic stewardship research. Most previous studies have been single-center, nonrandomized studies and have focused on larger hospitals with sufficient resources to support a comprehensive ASP. We used a multicenter, cluster-randomized design to study 3 interventions in 15 hospitals and incorporated both prepost and ITS analyses. The prepost design is the traditional design for cluster-randomized interventions, which evaluates differences in the impact of the intervention between program types. ITS analyses are often used in antibiotic stewardship intervention studies because they account for longitudinal changes in antibiotic prescribing.
Our design also compared 3 levels of antibiotic stewardship intensity, ranging from a relatively modest program with education and monthly antibiotic use data to a program that used a combination of local and remote ID expertise. Although our study was not designed to directly assess specific components of the ASPs, the most intense ASP in our study (program 3) involved daily feedback by an ID provider on specific patients, more extensive audit and feedback by local pharmacists, and frequent use of the ID hotline by clinicians. These frequent interactions with experts probably resulted in the local prescribers being more engaged and having greater trust in the stewardship process.
In the United States, there is a growing trend of hospitals joining healthcare systems and networks. In 2015, 66% of nonfederal hospitals were affiliated with a healthcare system (62% of all small hospitals), up from 50% in 1999 [8] . Healthcare systems and networks, like Intermountain, are well positioned are ratios of adjusted rates of antibiotic use in the intervention versus the baseline care periods. In the ITS analysis, the RRs for the comparison of each program versus baseline care are ratios of the adjusted rates of expected antibiotic use at the midpoint of the intervention period versus the expected adjusted rates from the baseline trend. For pairwise comparisons between programs, the RRs are ratios of the intervention versus baseline ratios between the programs being compared.
The 95% CIs are presented without adjustment for multiple comparisons for evaluations of the effects of programs 1, 2, and 3 compared with baseline care. Simultaneous 95% CIs accounting for 3 pairwise comparisons are presented for the comparisons between programs.
b For comparisons of programs 1, 2, and 3 versus baseline care, results are considered statistically significant if P < .05. To account for 3 pairwise comparisons among the program types, comparisons between programs are regarded as significant if P < .02.
to provide affiliated small hospitals resources and expertise to increase the efficiency and enhance the quality of healthcare delivery. Our most intense ASP benefited from the strength of Intermountain's system by using a centrally resourced program. Our data suggest that a healthcare system that centralizes antibiotic stewardship resources and shares them with affiliated small hospitals can achieve antibiotic reductions similar those demonstrated in larger hospitals. However, these delivery systems must allocate time and funding to allow experts to engage and partner with their affiliated small facilities to develop a sustainable and effective relationship. Embedding antibiotic stewardship support into healthcare delivery systems has the potential to engage small hospitals in antibiotic stewardship and allow for implementation of strategies known to be effective.
In contrast to small hospitals in healthcare systems, most independent small hospitals will lack access to ID expertise, technical infrastructure for antibiotic use measurement, and staff resources to develop an ASP that meets all CDC core elements. How these hospitals will develop and implement a robust ASP is unclear. Our experience suggests that independent small hospitals will need to identify a champion, access expert resources for assistance (ie, ID physicians), focus on syndromic-based stewardship methods targeting common conditions that are typically more prevalent in small hospitals, and adapt measurement to local capabilities for ASPs to be effective. Telehealth [28] and or other dissemination models (eg, Extension for Community Healthcare Outcomes [ECHO] [29] ) will need to be formally evaluated as possible mechanisms to provide this support.
Our study has several limitations. Hospitals were randomly assigned to an ASP, but the assignment was not blinded to the investigators or hospital staff. Site training and the enrollment process began several months before the formal initiation of the intervention, leading to changes in antibiotic use during the implementation period. This may have reduced the ability to demonstrate the effect of intervention but is probably reflective of real-world program implementation. Our within-program comparisons of each program were not randomized comparisons and are subject to bias from secular trends. However, the ITS analyses accounted for secular trends and gave similar point estimates to the prepost results. Each program included only 5 small hospitals, some of which had low patient volume. Although our study Figure 3 . Forest plot of rate ratios (RRs) for individual hospitals and program types-prepost analysis. Data represent ratios of adjusted rates comparing total and broad-spectrum antibiotic use between the intervention and baseline care periods within each hospital using prepost comparisons. The summary RRs for each program were estimated using a mixed-effects model. Hospital 2 was excluded from the analysis of broad-spectrum antibiotic use owing to insufficient use for model convergence.
included a modest total number of hospitals per program, an intervention study with significantly more small hospitals would be difficult to perform. There was heterogeneity in the effect of the intervention at individual hospitals, which probably reflects unmeasured differences in culture and implementation.
A formal assessment using an implementation science construct to evaluate the impact of qualitative and contextual factors on antibiotic prescribing is currently ongoing at Intermountain facilities. The small number of hospitals within each program and the heterogeneity of the effect limited the study's power to detect a difference in the effect size between the 3 program types. However, we did demonstrate a meaningful reduction in antibiotic use within program 3 hospitals compared with baseline. Intermountain is a technologically advanced healthcare system with robust information technology support, which may limit generalizability to facilities lacking such infrastructure. Finally, similar to other ASP studies, our study outcomes focused on measures of antibiotic utilization but not measures of appropriateness and may therefore have underestimated important benefits of antibiotic stewardship.
As of 1 January 2017, the Joint Commission now requires all hospitals, regardless of size, to have an ASP. How small hospitals will meet these regulatory requirements is unclear. We have demonstrated that within a healthcare delivery system, implementing ASPs in small hospitals was feasible and had an impact on antibiotic prescribing when central resources and ID expertise were used and local pharmacists were actively involved. Because small hospitals account for the majority of US hospitals and are least likely to have formal ASPs, ongoing national antibiotic stewardship efforts must address these settings and evaluate methods of implementation, regardless of healthcare network affiliation.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Figure 4 . Forest plot of rate ratios (RRs) for individual hospitals and program types-interrupted time series analysis. Data represent ratios between modeled adjusted rates of total and broad-spectrum antibiotic use at the midpoint of the intervention period versus the projected rates at the same time based on the trends from 2.5 years of baseline care data. Hospital 2 was excluded from the analysis of broad-spectrum antibiotic use owing to insufficient use for model convergence.
Notes
